Active substance
Results for the substance elranatamab
1 result
About this active substance
Elranatamab is an investigational monoclonal antibody used in the treatment of relapsed or refractory multiple myeloma. It works by directing the immune system's T cells against tumor cells, using an approach known as bispecific antibody therapy.
The medication is administered via subcutaneous injection and is intended for patients who have exhausted other therapeutic options. Clinical trials have shown a promising response rate, with significant tumor burden reduction in many patients.
Common side effects include cytokine release syndrome, fatigue, nausea, and fever. It is essential that treatment is administered under the supervision of a specialist, and patients should be monitored to prevent severe complications.
Elranatamab represents an innovation in multiple myeloma treatment, offering new hope to patients with advanced stages of the disease.
The medication is administered via subcutaneous injection and is intended for patients who have exhausted other therapeutic options. Clinical trials have shown a promising response rate, with significant tumor burden reduction in many patients.
Common side effects include cytokine release syndrome, fatigue, nausea, and fever. It is essential that treatment is administered under the supervision of a specialist, and patients should be monitored to prevent severe complications.
Elranatamab represents an innovation in multiple myeloma treatment, offering new hope to patients with advanced stages of the disease.